Alzamend Neuro Inc Stock Price, News & Analysis

Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that the FDA provided a framework for the clinical development of AL001, a lithium-delivery system for treating bipolar disorder, major depressive disorder, and PTSD. The ongoing Phase IIA trial evaluates AL001's safety and tolerability in Alzheimer's patients, with topline data expected in December 2022. Full results from a Phase I study indicated that AL001 is bioequivalent to lithium carbonate. Alzamend plans to submit IND applications for the additional indications upon completing the current trial.

Alzamend Neuro will present at the 12th Annual LD Micro Invitational from June 7-9, 2022, in Westlake Village, California. CEO Stephan Jackman will speak on June 8 at 12:00 p.m. PT, showcasing the company's accomplishments, including the completion of a Phase I study for AL001 and the initiation of a Phase IIA study. Alzamend is also preparing to submit an IND for AL002. The event will be accessible both live and virtually, with mandatory registration. More details can be found on their website.

Alzamend Neuro, Inc. (Nasdaq: ALZN) has submitted a Pre-IND meeting request to the FDA for its novel lithium-delivery system, AL001, targeting bipolar disorder, major depressive disorder, and PTSD. AL001 aims to deliver lithium's benefits while reducing toxicities. A Phase IIA trial for dementia related to Alzheimer's is ongoing, with topline data expected in December 2022. The trial evaluates safety and tolerability in patients with Alzheimer's. The company anticipates that AL001 may represent a significant improvement over existing lithium treatments, addressing a large patient population.

Alzamend Neuro (Nasdaq: ALZN) has initiated a 12-month Phase IIA multiple ascending dose study for AL001, aimed at patients with mild to moderate Alzheimer’s disease. The study's primary goal is to assess the safety, tolerability, and maximum tolerated dose of AL001, a novel lithium-delivery system designed to mitigate lithium's toxicities. The Phase I study confirmed AL001's bioequivalence to marketed lithium carbonate at a lower dosage. Topline data is expected by December 2022, marking a significant milestone for Alzamend in developing treatments for neurodegenerative diseases.

Alzamend Neuro (ALZN) has announced positive results from its Phase 1 trial for AL001, a new lithium-delivery system aimed at treating Alzheimer's disease. The data confirm that AL001 is bioequivalent to marketed lithium carbonate, establishing safety and tolerability. Based on these results, the company plans to initiate a Phase 2A multiple ascending dose study in May 2022. Additionally, Digital Power Lending, a subsidiary of BitNile Holdings (NILE), has invested $4 million in Alzamend, enabling the company to progress without seeking new capital.

BitNile Holdings, Inc. (NILE) announced an additional investment from its subsidiary, DP Lending, into Alzamend Neuro, Inc. (ALZN), totaling $4 million, following the achievement of key milestones in Alzamend's Phase 1 clinical trial for AL001. AL001 is designed as a potential treatment for Alzheimer's, leveraging a novel lithium-delivery system. BitNile now beneficially owns approximately 9.9 million shares of Alzamend and has rights to further invest. Successful progression through Phase 2A trials is anticipated.

BitNile Holdings Achieves 120% Revenue Growth

BitNile Holdings (NILE) reported a significant revenue increase of 120% to $52.4 million for the year ended December 31, 2021, up from $23.9 million in 2020. The company ended the year with total assets of $490 million and experienced a net loss reduction to $24.2 million. Key revenue growth drivers included lending and trading activities ($16.9 million) and cryptocurrency mining ($3.5 million).

Alzamend Neuro, Inc. (NASDAQ: ALZN) announced a partnership with Altasciences and iResearch Atlanta to conduct a Phase IIA multiple ascending dose study for AL001, a novel treatment for Alzheimer’s Disease. Enrollment is set to begin in May 2022. The Phase I study demonstrated that AL001 is bioequivalent to marketed lithium carbonate, indicating its potential safety and efficacy. This advancement may reduce the need for extensive Phase II and III studies. Alzamend aims to improve treatment options for Alzheimer's and related conditions.

Alzamend Neuro, Inc. (Nasdaq: ALZN) has appointed Dr. Terri Hunter to its Scientific Advisory Board. Dr. Hunter, a Technology Transfer Specialist with experience managing patents for Alzamend’s candidates AL001 and AL002, expresses enthusiasm for the company's progress in clinical trials. AL001 is a novel lithium-delivery system intended for Alzheimer’s treatment, aiming to provide benefits without current toxicities. Alzamend plans to begin a Phase 2 study involving Alzheimer's patients and submit an investigational new drug application for AL002 in Q2 2022.